Stayble Therapeutics

Stayble Therapeutics develops an injectable treatment against chronic low back pain triggered by disc degeneration. The treatment is presumed to last the patient’s entire life and require minimal rehabilitation.

Stayble Therapeutics

CEO:

Andreas Gerward

First investment year:

2016

Business sector:

Life Science, Drug development

Investment manager: Patrik Sjöstrand Visit website